Global neurological research has verified that a novel class of monoclonal antibodies successfully targets and clears amyloid-beta oligomers, significantly slowing the trajectory of early-stage dementia. In rigorous phase-three clinical trials, participants receiving regular intravenous infusions exhibited a measurable preservation of daily cognitive function and executive control compared to the placebo cohort. While this pharmacologic option does not restore dead neural pathways or offer a total cure, its ability to alter the underlying pathophysiological progression marks a milestone in modern neurobiology. Clinicians emphasize that patient selection is paramount, as the therapy is highly optimized for individuals demonstrating mild cognitive impairment verified through advanced neuroimaging. Ongoing monitoring protocols remain strict to catch potential micro-hemorrhages early, balancing clinical efficacy with stringent patient safety profiles.